Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10 (Adaptimmune Therapeutics plc)
(WorldNews Africa)

(Source: Adaptimmune Therapeutics plc) PHILADELPHIA and OXFORD, United Kingdom, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a Phase I triple tumor study using its wholly owned MAGE-A10 SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in patients with inoperable or metastatic urothelial cancer (transitional cell cancer of the bladder, ureter, or renal pelvis), melanoma, or squamous cell carcinoma of the head and neck. This is the first collaborative study under the recently announced multi-year strategic alliance between Adaptimmune and The University of Texas...